Anti-Human NTRK3 Recombinant Antibody Fab Fragment (6.4.1) (CAT#: TAB-182CQ-F(E))
The antibody significantly recognizes human and rat trkC and can be potentially used in the treatment of amyotrophic lateral sclerosis.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
Subcellular Location
Normal Tissue
RNA Expression
Figure 1 IF staining of human cell line A549
(Immunofluorescent staining of human cell line A549 shows localization to nucleoli & nuclear membrane.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/27484/if_selected.jpg
(Immunofluorescent staining of human cell line A549 shows localization to nucleoli & nuclear membrane.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/27484/if_selected.jpg
Figure 2 IF staining of human cell line U-2 OS
(Immunofluorescent staining of human cell line U-2 OS shows localization to nucleoli.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/48065/if_selected.jpg
(Immunofluorescent staining of human cell line U-2 OS shows localization to nucleoli.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/48065/if_selected.jpg
Figure 3 Cerebral cortex
(nuclear Neuronal cells Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous nuclear Neuropil Staining: High Intensity: Strong Quantity:>75% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_B_7_5.jpg
(nuclear Neuronal cells Staining: High Intensity: Strong Quantity: 75%-25% Location: Cytoplasmic/ membranous nuclear Neuropil Staining: High Intensity: Strong Quantity:>75% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_B_7_5.jpg
Figure 4 Colon
(nuclear Peripheral nerve/ganglion Staining: Medium Intensity: Moderate Quantity:>75% Location: Cytoplasmic/ membranous nuclear)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_A_8_3.jpg
(nuclear Peripheral nerve/ganglion Staining: Medium Intensity: Moderate Quantity:>75% Location: Cytoplasmic/ membranous nuclear)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_A_8_3.jpg
Figure 5 Testis
(nuclear Leydig cells Staining: Medium Intensity: Moderate Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_A_6_6.jpg
(nuclear Leydig cells Staining: Medium Intensity: Moderate Quantity: 75%-25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_A_6_6.jpg
Figure 6 Lymph node
(Non-nuclear)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_A_9_8.jpg
(Non-nuclear)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/9233/30817_A_9_8.jpg
Figure 7 RNA cell line category: Cell line enriched (U-138 MG)
(Cell lines ordered by descending RNA expression order)
* Image credit: Human Protein Atlas v21.proteinatlas.org/ENSG00000140538-NTRK3
(Cell lines ordered by descending RNA expression order)
* Image credit: Human Protein Atlas v21.proteinatlas.org/ENSG00000140538-NTRK3
Specifications
- Host Species
- Human
- Type
- Human antibody
- Specificity
- Human
- Species Reactivity
- Human, Rat
- Clone
- 6.4.1
- Applications
- Used for immunoassay techniques such as: Enzyme-linked Immunosorbent Assay; Western Blot
- Related Disease
- Amyotrophic lateral sclerosis (ALS)
Target
- Alternative Names
- NTRK3; Neurotrophic receptor tyrosine kinase 3; TRKC; gp145(trkC); NT-3 growth factor receptor; GP145-TrkC; ETV6-NTRK3 fusion; tyrosine kinase receptor C; ETS related protein-neurotrophic receptor tyrosine kinase fusion protein
- Gene ID
- 4916
- UniProt ID
- Q96CY4
Related Resources
EGFR Tyrosine Kinase Inhibitor Resistance
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone 6.4.1"
See other products for "NTRK3"
Select a product category from the dropdown menu below to view related products.
Please select product type
IgG Antibody Products
Mouse Antibody Products
Human Antibody Products
Rabbit Monoclonal Antibody Products
ScFv Antibody Products
Fab Antibody Products
Extracellular Vesicle (EV) Antibody Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-2174z | Mouse Anti-NTRK3 Recombinant Antibody (clone 36A5) | WB, ELISA, FC, ICC, IF, IHC | Mouse IgG1 |
| HPAB-0198-CN | Human Anti-NTRK3 Recombinant Antibody (HPAB-0198-CN) | ELISA, ICC | Human IgG2a, κ |
| VS3-XY1193 | Mouse Anti-NTRK3 Recombinant Antibody (clone 4G5) | ELISA, WB | Mouse IgG1 |
| VS3-XY1194 | Mouse Anti-NTRK3 Recombinant Antibody (clone 7H6) | ELISA, WB, IHC | Mouse IgG1 |
| VS3-WK1038 | Mouse Anti-NTRK3 Recombinant Antibody (VS3-WK1038) | WB | Mouse IgG1, κ |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-182CQ-F(E). Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: ELISA, WB, Neut, Funcs, IHC, Inhib
Application: WB, ELISA, IF, FuncS, Apop, BA
Application: FC, IHC, Cyt, FuncS
Application: ELISA, IF, Block, FuncS
Application: Neut, IHC, Activ, FuncS, IF, ELISA
Application: ELISA, FC, Neut, Inhib
For Research Use Only. Not For Clinical Use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
